hotspot -WSS

hotspot

author：hotspot 2025-10-02 19:39:05 - browse：5

Adam's take main illustration — Molly Ferguson/STAT

CHICAGO — Something is off about the way Novartis is talking about pelabresib, its newly acquired and costly treatment for myelofibrosis. I suspect the Swiss pharma giant’s previously stated plan to submit a marketing application to the Food and Drug Administration this year has been blocked.

I’m not just speculating wildly. It’s looking increasingly likely that the $3 billion purchase of MorphoSys to acquire pelabresib — a deal pushed hard by top Novartis executive strategist Ronny Gal over some internal dissent — has run into serious trouble just days after the closing.

On Sunday evening, Novartis Chief Medical Officer Shreeram Aradhye, speaking at the company’s ASCO investor event here in Chicago, offered this response to an analyst who asked about pelabresib.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Senate panel to vote on hospitals, PBMs, prisoner care

focus

WSS

The struggle to figure out which patients 'deserve' Wegovy

Transgender sports debate: Physicians say bans are health issue

Neurocrine congenital adrenal hyperplasia trial succeeds

David Liu startup to focus on CRISPR delivery

The FDA weighs the risks of candy

Assistant physicians can help address the primary care shortage

leisure time

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

hotspot

Alkermes shareholders re

Physician subsidies by hospitals soar in wake of No Surprises Act

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Biden's order seeks to regulate AI risk without stifling innovation

At least 13 dead in Texas as scorching temps continue

Assistant physicians can help address the primary care shortage

Hepatitis C has a cure — but many Americans still lack access to it

The struggle to figure out which patients 'deserve' Wegovy

Virginia high school admissions case could be legal follow

People with substance use disorder deserve online privacy

focus

Free Covid tests will again be offered to all U.S. households

Hospitals warn Medicare's drug payment fix is ‘unlawful’

Eli Lilly to pay $200M for Beam’s stake in gene

How the messy conversation about Dolly changed bioethics

Testing for cancer recurrence creates a new limbo for patients

Telehealth options flood the market as retailers push virtual care

leisure time

hotspot

focus

entertainment